A $100 krypton chloride excimer lamp needs no new science, only scale

A $100 krypton chloride excimer lamp, Nathan Grubaugh argues, requires no new science. The price drop he describes would come entirely from manufacturing scale and market competition. His timeframe is the next couple of years, or possibly sooner.

Grubaugh’s call matters because far-UVC germicidal lighting, which uses 222-nanometer wavelengths to inactivate airborne pathogens without the tissue damage associated with conventional ultraviolet light, has been commercially bottlenecked primarily by cost. At several hundred dollars per unit, the lamps remain largely confined to institutional buyers with dedicated procurement budgets. The economic argument for putting one in a home office, a classroom, or a waiting room stays weak at that price. At $100, it changes substantially.

The bet Grubaugh is making is an industrial one, not a scientific one. He is not forecasting a breakthrough in lamp efficiency, a new emitter design, or a shift in the underlying chemistry. The price he cites is available, in his view, through the ordinary mechanics of volume manufacturing and competitive market entry. Both of those inputs are observable. Either manufacturers build sufficient volume to compress per-unit costs, or they do not. Either new entrants compete on price aggressively enough to push incumbents down the cost curve, or the market stays thin and pricing stays elevated. No laboratory result is required for the forecast to resolve.

You know if we get I don't think there's any reason that in the you know near future next couple years or so or even sooner that the price couldn't be no on the order of a hundred bucks per lamp and that's you know with zero technological innovation of any sort Nathan Grubaugh

The specific conditions under which the call fails are worth stating plainly. If demand stalls before scale can be achieved, per-unit costs remain elevated regardless of how much capacity exists in principle. If regulatory friction around far-UVC products in residential settings slows adoption in major consumer markets, the competitive pressure that would otherwise drive prices down does not build. And if the technical support burden that currently accompanies lamp procurement turns out to be a structural feature of the product rather than a symptom of market immaturity, the consumer addressable market stays narrow no matter how cheap the lamp itself becomes. Any of those conditions could invalidate the call within the stated timeframe without Grubaugh’s underlying economic logic being wrong.

What the $100 threshold would actually do to the market is a separate question from whether it is achievable, and it is worth holding the two apart. Institutional deployment, in hospitals, transit systems, and schools, has driven most of the growth in far-UVC so far. Those buyers have facility managers, infection-control specialists, and procurement processes designed to evaluate new lighting technology before it goes into a space. A consumer price point introduces a different buyer: one making unguided purchasing decisions, often without expert input on placement, maintenance cycles, or safe operating conditions. Whether mass consumer adoption of germicidal lighting is straightforwardly beneficial, or whether it introduces its own complications around misuse and unverified efficacy claims, is a live question that the price forecast alone does not answer.

None of that uncertainty changes the structure of Grubaugh’s bet. He is making a claim about manufacturing economics, assigning it a horizon of roughly two years, and grounding it in the observation that the cost reduction requires nothing that does not already exist. That is a more falsifiable forecast than most technology price predictions, which tend to depend on research outcomes that can slip indefinitely. This one depends on factories, competition, and demand, all of which move in observable ways. The lamp price either crosses $100 within the window or it does not, and the inputs that would drive it there are visible before the deadline arrives.

The broader significance of the call is that it frames far-UVC’s adoption ceiling as an economic problem with a near-term solution, not a technical problem awaiting a future breakthrough. If Grubaugh is right, the question shifts from whether germicidal lighting at scale is possible to whether the institutions and individuals who might use it are ready to absorb a product that becomes affordable before the surrounding infrastructure, standards, consumer guidance, and regulatory clarity, has fully caught up. That is a different kind of challenge, and arguably a more tractable one. The lamp price crossing $100 would not end the adoption debate. It would move it to a different set of arguments entirely.